ArticleGastroenterology2014
Signatures of protective memory immune responses during hepatitis C virus reinfection.
Article in Gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 62 citations in OpenAlex.
- Hepatitis C virus-specific CD4+ T cell phenotype and function in different infection outcomes.The Journal of clinical investigation · 2020Trial
- Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy.Journal of acquired immune deficiency syndromes (1999) · 2016Trial
- Observational
- Functional Antigen-Specific CD8 TEuropean journal of immunology · 2025Article
- Broadly Neutralizing Antibody Characteristics in Hepatitis C Virus Infection and Implications for Vaccine Design.Vaccines · 2025Review
- Coordinated expansion of memory T follicular helper and B cells mediates spontaneous clearance of HCV reinfection.Frontiers in immunology · 2024Article
- Lasting differential gene expression of circulating CD8 T cells in chronic HCV infection with cirrhosis identifies a role for Hedgehog signaling in cellular hyperfunction.Frontiers in immunology · 2024Article
- Immunological Monitoring in Hepatitis C Virus Controlled Human Infection Model.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Factors Associated with Spontaneous Clearance of Recently Acquired Hepatitis C Virus among HIV-Positive Men in Brazil.Viruses · 2023Review
- TROLLOPE: A novel sequence-based stacked approach for the accelerated discovery of linear T-cell epitopes of hepatitis C virus.PloS one · 2023Article
- Differential immune transcriptomic profiles between vaccinated and resolved HCV reinfected subjects.PLoS pathogens · 2022Article
- Cathepsin B and Plasma Kallikrein Are Reliable Biomarkers to Discriminate Clinically Significant Hepatic Fibrosis in Patients with Chronic Hepatitis-C Infection.Microorganisms · 2022Article
- Tissue-resident memory T cells in chronic liver diseases: Phenotype, development and function.Frontiers in immunology · 2022Review
- T cell responses during HBV and HCV infections: similar but not quite the same?Current opinion in virology · 2021Review
- Towards a Systems Immunology Approach to Understanding Correlates of Protective Immunity against HCV.Viruses · 2021Review
- Expansion of Unique Hepatitis C Virus-Specific Public CD8Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Immune system control of hepatitis C virus infection.Current opinion in virology · 2021Review
- T-Cell Immunity against the Hepatitis C Virus: A Persistent Research Priority in an Era of Highly Effective Therapy.Cold Spring Harbor perspectives in medicine · 2021Review
- A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection.Frontiers in immunology · 2021Review
- Hepatitis C virus vaccine design: focus on the humoral immune response.Journal of biomedical science · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND &
aimsDevelopment of a vaccine against hepatitis C virus (HCV) has been hindered by our limited understanding of immune correlates of protection during real-life exposure to the virus. We studied the immune response during HCV reinfection.
methodsWe analyzed blood samples from participants in the Montreal Acute Hepatitis C Injection Drug User Cohort Study who were reinfected with HCV from 2009 to 2012. Five patients spontaneously resolved their second infection and 4 developed chronic infections. We monitored the phenotypic and functional dynamics of HCV-specific memory T cell responses in all subjects during natural re-exposure and re-infection.
resultsPopulations of CD4(+) and CD8(+) T cells with HCV-specific polyfunctional memory were expanded in all 5 individuals who resolved 2 successive HCV infections. We detected CD127(hi) HCV-specific memory CD8(+) T cells before reinfection regardless of a subject's ability to clear subsequent infections. Protection against viral persistence was associated with the expansion of a CD127(neg), PD1(lo) effector memory T cells at the peak of the response. We also observed broadening of T-cell response, indicating generation of de novo T-cell responses. The 4 individuals who failed to clear their subsequent infection had limited expansion of HCV-specific CD4(+) and CD8(+) memory T cells and expressed variable levels of the exhaustion marker PD1 on HCV-specific CD8(+) T cells. Dominant epitope regions of HCV strains isolated from patients with persistent reinfection had sequence variations that were not recognized by the pre-existing memory T cells.
conclusionsProtection from persistent HCV reinfection depends on the magnitude, breadth, and quality of the HCV-specific memory T-cell response. Sequence homology among viruses and ability of T cells to recognize multiple strains of HCV are critical determinants of protective memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.